Epix tests MRI blood clot agent in phase II trial :
This article was originally published in Clinica
Executive Summary
Epix Pharmaceuticals is starting a phase II proof-of-concept trial for its EP-2104R MRI-based agent for detecting blood clots throughout the body. The study's launch follows the completion late last year of a phase I trial that showed the agent to be well tolerated by healthy subjects at all doses tested. The phase II programme, which is expected to enrol around 40 patients, is being conducted at multiple clinical sites worldwide. Cambridge, Massachusetts-based Epix is collaborating on EP-2104R's development with German firm Schering.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.